hero section gradient
12 handpicked stocks

India's U.S. Solar Expansion

Indian solar manufacturers are winning big contracts in America, creating exciting investment opportunities. This collection features carefully selected companies across both countries, from panel makers to project developers, all set to benefit from this cross-border solar boom.

Author avatar

Han Tan | Market Analyst

Published on July 1

Your Basket's Financial Footprint

Market capitalisation breakdown for the basket.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and returns that likely track broader market movements.
  • Generally suited as a core holding, not for speculative trading.
  • Likely to deliver steady long-term appreciation, not rapid short-term gains.
Total Market Cap
  • FSLR: $24.33B

  • ENPH: $4.85B

  • SEDG: $2.30B

  • Other

About This Group of Stocks

1

Our Expert Thinking

The recent 540 MW contract win by Waaree Energies signals a major shift in the solar landscape. This collection captures both Indian manufacturers expanding globally and the U.S. companies that will benefit from this reliable supply chain, creating a complete picture of this cross-border growth story.

2

What You Need to Know

These stocks span the entire solar value chain - from raw material producers and panel manufacturers to project developers and component suppliers. They provide exposure to both immediate infrastructure growth and long-term clean energy adoption across two of the world's largest renewable markets.

3

Why These Stocks

Each company was selected for its direct connection to the India-U.S. solar corridor. Some are positioned to export manufacturing capacity to America, while others will utilize these components in projects. Together, they represent the most promising opportunities in this emerging trend.

Why You'll Want to Watch These Stocks

🌎

Global Green Bridge

This isn't just another solar play—it's a unique cross-border opportunity connecting two massive markets. As India's manufacturing might meets America's renewable appetite, these companies stand at the perfect intersection.

💰

Following the Money Flow

With a 540 MW deal already inked and more likely coming, billions of dollars will flow through this supply chain. These companies are positioned to capture significant revenue as U.S. solar development accelerates.

🔋

Beyond Short-Term Gains

While immediate project wins create excitement, this collection offers exposure to the long-term shift in global solar trade. As India becomes a manufacturing powerhouse, these relationships and market positions will only strengthen.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions